Zero-Order Methylphenidate Release via Barrier Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methylphenidate formulations exhibit rapid peak blood levels and short half-life, leading to uneven drug release and increased side effects, making it difficult to maintain consistent plasma concentrations and requiring frequent dosing, which is undesirable for patient compliance and side effect management.
Innovation Solution
A modified release solid dosage form comprising a matrix core with a non-swellable hydrophobic material and a water-soluble pharmaceutical agent, coated with a hydrophobic polymer and hydrophilic pore-forming agent, and a water-soluble barrier coating to achieve zero-order release kinetics for 6 to 10 hours, reducing dosing frequency and minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If a conventional immediate release dosage form is used, then the drug is rapidly released into the bloodstream, but this causes peak blood levels and short half-life leading to uneven drug release and increased side effects
Solution Approach 1:
The patent employs a porous hydrophilic matrix material (such as HPMC - hydroxypropyl methylcellulose) as the core formulation. This porous structure allows controlled water penetration and drug dissolution, enabling the drug to be released at a steady rate rather than rapidly. The porosity facilitates uniform drug distribution and controlled diffusion, achieving zero-order release kinetics that maintain consistent plasma concentrations and reduce peak-level side effects.
Solution Approach 2:
The patent uses a composite formulation combining hydrophilic matrix materials (HPMC, starch, or sugar) with the pharmaceutical agent. This composite structure creates a gel barrier upon contact with gastrointestinal fluids, which controls drug release. The composite nature of the matrix provides both structural integrity and controlled release properties, transforming the rapid release characteristic of immediate-release forms into sustained zero-order release.
2Reliability
If a zero-order release dosage form is formulated for highly water soluble pharmaceutical agents, then uniform drug release is achieved, but the agents are susceptible to dose dumping
Solution Approach 1:
The patent modifies the physical and chemical parameters of the formulation by using specific ratios of hydrophilic matrix materials and controlling the drug load within certain ranges. It also controls coating thickness and composition parameters. These parameter optimizations ensure that the dosage form maintains its zero-order release characteristics while preventing dose dumping, even for highly water-soluble agents.
Solution Approach 2:
The patent introduces a coating layer as an intermediary barrier between the hydrophilic matrix core and the external environment. This coating (which may be enteric or controlled-release coating) acts as a mediator that prevents premature drug release in the stomach while allowing controlled release in the intestine. The coating protects the water-soluble drug from direct contact with gastric fluids, eliminating dose dumping risk while maintaining uniform release characteristics.
3Reliability
If frequent dosing is administered to maintain consistent plasma concentrations, then therapeutic effectiveness is improved, but patient compliance deteriorates
Solution Approach 1:
The patent formulates the dosage form to provide extended-release action that covers the entire therapeutic window (typically 12-24 hours). By designing the release profile to maintain effective drug concentrations throughout the dosing interval, the patent eliminates the need for frequent dosing while preserving therapeutic effectiveness. The zero-order release ensures that drug levels remain within the therapeutic range without requiring multiple daily administrations, thereby improving patient compliance.
4Reliability
If a complex coating process is applied to achieve zero-order release, then drug release uniformity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent optimizes coating parameters including thickness, composition ratios, and application conditions to achieve the desired zero-order release profile. By carefully controlling these parameters within specific ranges, the patent achieves reliable drug release uniformity while avoiding excessively complex manufacturing processes. The use of commercially available coating materials and standard coating equipment further simplifies manufacturing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dosage form provides sustained zero-order release of methylphenidate, maintaining consistent drug levels, reducing the risk of dose dumping, and allowing for once-daily administration, thereby improving patient compliance and minimizing side effects.
Implementation Method 1
a modified release solid dosage form comprising a matrix core with a non-swellable hydrophobic material and a water-soluble pharmaceutical agent, coated with a hydrophobic polymer and hydrophilic pore-forming agent
Implementation Method 2
coated with a hydrophobic polymer and hydrophilic pore-forming agent
Implementation Method 3
a water-soluble barrier coating to achieve zero-order release kinetics
Data Source
AI summary
The invention comprises a solid dosage form for delivery of water soluble pharmaceutical agents. The solid dosage form comprises a matrix core containing the pharmaceutical agent and a hydrophobic material; a modified release coating containing a hydrophilic pore-forming agent and a hydrophobic polymer; and a water-soluble barrier coating between the modified release coating and the matrix core. The dosage form exhibits a zero-order release profile upon dissolution.